TherapeuticsMD, Inc. (TXMD)
2.21
-0.03
(-1.34%)
USD |
NASDAQ |
Sep 04, 16:00
2.17
-0.04
(-1.81%)
After-Hours: 20:00
TherapeuticsMD Gross Profit Margin (Quarterly) : 62.14% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 62.14% |
| March 31, 2026 | 55.11% |
| December 31, 2025 | -1.46% |
| September 30, 2025 | 87.76% |
| June 30, 2025 | 89.92% |
| March 31, 2025 | 75.83% |
| December 31, 2024 | 85.01% |
| September 30, 2024 | 82.45% |
| June 30, 2024 | 23.08% |
| March 31, 2024 | 57.51% |
| December 31, 2023 | -26.89% |
| September 30, 2023 | |
| June 30, 2023 | 70.71% |
| March 31, 2023 | 93.51% |
| September 30, 2022 | -77.12% |
| June 30, 2022 | -81.03% |
| March 31, 2022 | -47.34% |
| December 31, 2021 | 74.64% |
| September 30, 2021 | 79.21% |
| June 30, 2021 | 82.04% |
| March 31, 2021 | 76.41% |
| December 31, 2020 | 74.11% |
| September 30, 2020 | 81.71% |
| June 30, 2020 | 56.48% |
| March 31, 2020 | 75.70% |
| Date | Value |
|---|---|
| December 31, 2019 | 80.33% |
| September 30, 2019 | 93.31% |
| June 30, 2019 | 77.56% |
| March 31, 2019 | 77.96% |
| December 31, 2018 | 79.45% |
| September 30, 2018 | 77.76% |
| June 30, 2018 | 86.19% |
| March 31, 2018 | 81.63% |
| December 31, 2017 | 84.22% |
| September 30, 2017 | 82.91% |
| June 30, 2017 | 82.71% |
| March 31, 2017 | 82.20% |
| December 31, 2016 | 83.11% |
| September 30, 2016 | 76.92% |
| June 30, 2016 | 73.78% |
| March 31, 2016 | 77.12% |
| December 31, 2015 | 77.73% |
| September 30, 2015 | 76.68% |
| June 30, 2015 | 78.40% |
| March 31, 2015 | 76.38% |
| December 31, 2014 | 79.05% |
| September 30, 2014 | 74.17% |
| June 30, 2014 | 75.82% |
| March 31, 2014 | 70.19% |
| December 31, 2013 | 83.43% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
| Veru, Inc. | -- |
| Johnson & Johnson | 68.73% |
| Eli Lilly & Co. | 85.78% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -1.09% |
| Return on Assets | -0.78% |
| Return on Invested Capital | -0.89% |
| Profit Margin (Quarterly) | 18.87% |
| Operating Margin (Quarterly) | -92.41% |
| Return on Net Operating Assets | -3.06% |